A practical reference on evidence base: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Nanoscale secondary ion mass spectrometry (NanoSIMS) is an analytical instrument manufactured by CAMECA which operates on the principle of secondary ion mass spectrometry. The NanoSIMS is used to acquire nanoscale resolution measurements of the elemental and isotopic composition of a sample. The NanoSIMS is able to create nanoscale maps of elemental or isotopic distribution, parallel acquisition of up to seven masses, isotopic identification, high mass resolution, subparts-per-million sensitivity with lateral resolution down to 30 nm.
== See also == Hermetic seal – Airtight seal James Webb Space Telescope sunshield – Main cooling system for the infrared observatory Tervis Tumbler – American drinkware manufacturer Thermal cooking – Cooking method Yeti Holdings – American manufacturing company Cooler – Insulated box used to keep food or drink cool
In 2003–04, SOCPAC supported the AFP by training a larger number of Filipino forces. Again, 1st SFG deployed two successive force packages, consisting of one ODB and 5 ODAs, to conduct Security Assistance during 2003, and a third force package in 2004 of one ODB and 3 ODAs. In total the ODAs trained 5 AFP army and one AFP marine battalions. During the same period, 1st Battalion of 1st SFG continued training the Filipino Counterterrorist force, preparing and outfitting an additional two Light Reaction Companies (LRCs). ODAs from 1st Battalion of 1st SFG also assisted in the design of a Joint Special Operations Group (JSOG), including AFP air force rotary wing lift assets. On 30 June 2004, a U.S. Special Forces soldier from 2nd Battalion, 1st SFG, was killed in a non-hostile incident in Manila. SOCPAC also introduced Operations/Intelligence Fusion Teams (O/IFTs) to work with various organizations in AFP's Southern Command. The O/IFTs provided advice and assistance on collection priorities and force employment at division and brigade. Beginning in 2004, 1st Battalion 1st SFG provided two ODAs continuously to serve as O/IFTs, both to the newly created JSOG and to Filipino 6th Infantry Division in Mindanao. In the summer of 2005, terrorists from the ASG and JI had moved from Mindanao to Sulu where they sought refuge.
Sources: en.wikipedia.org
Additionally, some monastic orders follow a pescatarian diet, and members of the Eastern Orthodox Church follow a vegan diet during fasts. There is also a strong association between the Quakers and vegetarianism dating back at least to the 18th century. The association grew in prominence during the 19th century, coupled with growing Quaker concerns in connection with alcohol consumption, anti-vivisection and social purity. The association between the Quaker tradition and vegetarianism, however, becomes most significant with the founding of the Friends' Vegetarian Society in 1902 "to spread a kindlier way of living amongst the Society of Friends."
==== Eurasian plate ==== Eifel hotspot (8) 50°12′N 6°42′E, w= 1 az= 082° ±8° rate= 12 ±2 mm/yr Iceland hotspot (14) 64°24′N 17°18′W Eurasian Plate, w= 0.8 az= 075° ±10° rate= 5 ±3 mm/yr North American Plate, w= 0.8 az= 287° ±10° rate= 15 ±5 mm/yr Possibly related to the North Atlantic continental rifting (62 Ma), Greenland. Azores hotspot (1) 37°54′N 26°00′W Eurasian Plate, w= 0.5 az= 110° ±12° North American Plate, w= 0.3 az= 280° ±15° Jan Mayen hotspot (15) 71°00′N 9°00′W Hainan hotspot (46) 20°00′N 110°00′E, az= 000° ±15°
In a lecture on 14 September 2007, Dietmar von Reeken described the emergence of a "Lower Saxony consciousness" in the 19th century, the geographical basis of which was used to invent a territorial construct: the resulting local heritage societies (Heimatvereine) and their associated magazines routinely used the terms "Lower Saxony" or "Lower Saxon" in their names. At the end of the 1920s in the context of discussions about a reform of the Reich, and promoted by the expanding local heritage movement (Heimatbewegung), a 25-year conflict started between "Lower Saxony" and "Westphalia". The supporters of this dispute were administrative officials and politicians, but regionally focussed scientists of various disciplines were supposed to have fuelled the arguments. In the 1930s, a real Lower Saxony did not yet exist, but there were a plethora of institutions that would have called themselves "Lower Saxon". The motives and arguments in the disputes between "Lower Saxony" and "Westphalia" were very similar on both sides: economic interests, political aims, cultural interests and historical aspects.
Sources: en.wikipedia.org
=== Diet === People with autoimmune hyperthyroidism (such as in Graves' disease) should not eat foods high in iodine, such as edible seaweed and seafood. From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower rates of disease and goiters, and improved the lives of children whose mothers would not have eaten enough iodine during pregnancy, which would have lowered the IQs of their children.
=== 2010–2012: Early growth === Blockchain analysts estimate that Nakamoto had mined about one million bitcoins before he disappeared in 2010 and handed the network alert key and control of the code repository over to Gavin Andresen. Andresen later became lead developer at the Bitcoin Foundation, an organization founded in September 2012 to promote bitcoin. After early "proof-of-concept" transactions, the first major users of bitcoin were black markets, such as the dark web Silk Road. During its 30 months of existence, beginning in February 2011, Silk Road exclusively accepted bitcoins as payment, transacting ₿9.9 million, worth about $214 million.
Major (Acting Lieutenant Colonel) Graham Evan William Tudor Raikes (510624), Adjutant General's Corps (SPS). 24565384 Warrant Officer Class 2 John Joseph Richards, Adjutant General's Corps (RMP). W0801011 Staff Sergeant Sandra Robson, The Royal Logistic Corps. Major Philip James Francois Schofield (495231), The Royal Green Jackets. Major Michael Peter Shapland (504505), Royal Tank Regiment. Major Alistair Colin Sheppard (508235), Corps of Royal Engineers. Acting Lieutenant Colonel Robin Fitzroy Somerset (414981), Winchester College Combined Cadet Force, Territorial Army. 24386268 Warrant Officer Class 2 Kevin Stewart, Royal Regiment of Artillery. Captain John Sutherland (537667), The Highlanders. Major Leslie Harris-Ward, , (502300), The Parachute Regiment (Volunteers), Territorial Army. Major Robert William Warren (513382), Adjutant General's Corps (RMP). Overseas Award Lieutenant Wong Hon Wing (538568), General List. Royal Air Force Flight Sergeant Ronald John Bennett (D8011572). Flight Lieutenant Ian Michael Beresford (8151887). Warrant Officer George Arthur Biddleston (D8068720). Sergeant Karl Richard Brown (D8126056). Flight Lieutenant (now Squadron Leader) Stephen John Butler (8080431). Squadron Leader Sean Chiddention (8028456). Flight Lieutenant Andrew Cubin (8027993). Flight Lieutenant Neil Cummings (3145881), Royal Air Force Volunteer Reserve (Training). Corporal Anthony David Deacon (R8198216). Squadron Leader Brian Dean (4278701), (Retired). Junior Technician Peter Doherty (E8254300). Corporal Christine Doyley (E8233551).
In any case, the levels of most steroid hormones, including testosterone and cortisol, are usually unchanged by spironolactone in humans, which may in part be related to compensatory upregulation of their synthesis. The weak steroidogenesis inhibition of spironolactone might contribute to its antiandrogenic efficacy to some degree and may explain its side effect of menstrual irregularities in women. However, its androgen synthesis inhibition is probably clinically insignificant. Spironolactone has been found in some studies to increase levels of estradiol, an estrogen, although many other studies have found no changes in estradiol levels. The mechanism of how spironolactone increases estradiol levels is unclear, but it may involve inhibition of the inactivation of estradiol into estrone and enhancement of the peripheral conversion of testosterone into estradiol. It is notable that spironolactone has been found in vitro to act as a weak inhibitor of 17β-hydroxysteroid dehydrogenase 2, an enzyme that is involved in the conversion of estradiol into estrone. Increased levels of estradiol with spironolactone may be involved in its preservation of bone density and in its side effects such as breast tenderness, breast enlargement, and gynecomastia in women and men. In response to the antimineralocorticoid activity spironolactone, and in an attempt to maintain homeostasis, the body increases aldosterone production in the adrenal cortex. Some studies have found that levels of cortisol, a glucocorticoid hormone that is also produced in the adrenal cortex, are increased as well.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.